Preventing platinum-induced ototoxicity in children - Is there a potential role for sodium thiosulfate?

Pediatric Blood and Cancer

Volumn 47, Issue 2, 2006, Pages 120-122

  Skinner, Roderick ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; PLATINUM DERIVATIVE; SODIUM THIOSULFATE;

CHILD; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; HEARING LOSS; HIGH RISK POPULATION; HUMAN; HYPERNATREMIA; NOTE; OTOTOXICITY; PRIORITY JOURNAL; SOCIAL ASPECT; SPEECH DEVELOPMENT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARBOPLATIN; CHELATING AGENTS; CHILD; CHILD, PRESCHOOL; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; PLATINUM COMPOUNDS; THIOSULFATES;

EID: 33745773687     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20627     Document Type: Note

References (17)

1. McHaney VA, Thibadoux G, Hayes FA, et al. Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 1983;102: 314-317.
2. Schell MJ, McHaney VA, Green AA, et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol 1989;7:754-760.
3. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 1991;19: 295-300.
4. Skinner R, Pearson ADJ, Amineddine HA, et al. Ototoxicity of cisplatinum in children and adolescents. Br J Cancer 1990;1990: 927-931.
5. Ruiz L, Gilden J, Jaffe N, et al. Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis- diamminedichloroplatinum(II). Cancer Res 1989;49:742-744.
6. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004;26:649-655.
7. Stohr W, Langer T, Kremers A, et al. Hearing function in soft tissue sarcoma patients after treatment with carboplatin: A report from the Late Effects Surveillance System. Oncol Rep 2004;12:767-771.
8. Bergeron C, Dubourg L, Chastagner P, et al. Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: Results of the SFOP NBL90 study. Pediatr Blood Cancer 2005;45:32-36.
9. Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998;22:669-674.
10. Punnett A, Bliss B, Dupuis LL, et al. Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort study. Pediatr Blood Cancer 2004;42:598-603.
11. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brian tumors. Clin Cancer Res 2001;7:493-500.
12. Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer 2004;40:2352-2354.
13. Li U, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: The influence of age and cumulative dose. Eur J Cancer 2004;40:2445-2451.
14. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin- induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996;14:2101-2112.
15. Schuchter LM, Hensley MT, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002;20:2895-2903.
16. Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 2004;43:780-784.
17. Craft AW, Pearson AJ. Three decades of chemotherapy for childhood cancer: From cure at any cost to cure at least cost. Cancer Surveys 1989;8:605-629.